Outpatient prescription sales of multinational pharmaceutical companies in Korea had slowed down in general last year. Viatris held the lead among multinational pharmaceutical companies for two consecutive years, but its amount of prescriptions also decreased 0.3% compared to the previous year. The top prescription drug companies such as MSD (Organon), AstraZeneca, Novartis, Astellas, all saw a decline in sales.

According to the market research institution UBIST on the 26th, Viatris Korea held the lead in outprescription sales with ₩463.9 billion among multinational manufacturing companies last year. The total prescription amount of the company had fallen 0.3% compared to the ₩465.4 billion in